Secretory dynamics of bioactive and immunoreactive prolactin in polycystic ovary syndrome

R. E. Anderson, Z. Ben-Rafael, G. L. Flickinger, F. Meloni, R. B. Barnes, G. F. Rosen, R. A. Lobo

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


To further investigate prolactin (PRL) secretion in polycystic ovary syndrome (PCO), the authors evaluated immunoreactive (immuno) and bioactive (bio) PRL levels in the basal state and in response to provocative testing with intravenous dopamine (DA), metoclopramide (MCP), and gonadotropin-releasing hormone (GnRH), before and after disulfiram. Basal measurements of immuno-PRL, bio-PRL, and the ratio of bio/immuno-PRL were similar in PCO and controls. The immuno-PRL, decrement after DA was greater than that of bio-PRL in both groups (P < 0.05). After MCP, immuno-PRL increased more than bio-PRL in PCO (P < 0.01), and this immuno-PRL increment was greater than that of controls (P < 0.05). Bio-PRL and immuno-PRL increased after GnRH in PCO, but not controls, and these responses were inhibited by disulfiram. These data confirm PRL hypersecretion in some women with PCO, which is better expressed by immunoreactivity than bioactivity. Given the assay systems and patients studied, bioactivity of PRL appears to be normal in PCO.

Original languageEnglish (US)
Pages (from-to)239-243
Number of pages5
JournalFertility and Sterility
Issue number2
StatePublished - 1988

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'Secretory dynamics of bioactive and immunoreactive prolactin in polycystic ovary syndrome'. Together they form a unique fingerprint.

Cite this